SWOG clinical trial number
S0309
Myeloma Specimen Repository Protocol, Ancillary
Closed
Phase
Research committees
Myeloma
Eligibility Criteria Expand/Collapse
Pts must be currently registered on a Southwest Oncology Group treatment study (SWOG or Intergroup) for multiple myeloma, smoldering myeloma, Waldenstrom's macroglobulinemia, monoclonal gammopathy of undetermined significance, or amyloidosis. Pts who are already enrolled on active SWOG treatment protocols are eligible for this study. A minimum of 3 ml of bone marrow aspirate and at least one tube of blood (preferably two tubes of blood), will be collected from each pt. Pretreatment specimens must be submitted to be eligible for this study. A pt may be registered on this protocol only once. If a pt on this study subsequently enters another treatment protocol related to this study, then specimens can be submitted according to the procedures of this protocol, and the pt need not be registered again on this study.
Other Clinical Trials
SWOG Clinical Trial Number
S2213
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Research Committee(s)
Myeloma
Activated
12/01/2023
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
S2209
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Frontline Regimen Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd) Followed by Len+/-Dara (R+/-D) Maintenance
Research Committee(s)
Myeloma
Activated
05/30/2023
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
S2005
A PHASE II RANDOMIZED STUDY COMPARING IBRUTINIB AND RITUXIMAB VS. VENETOCLAX AND RITUXIMAB IN PREVIOUSLY UNTREATED WALDENSTROM'S MACROGLOBULINEMIA (WM) /LYMPHOPLASMACYTIC LYMPHOMA (LPL)
Research Committee(s)
Myeloma
Activated
06/24/2021
Accrual
10%
Open
Phase